Maternal antibody at delivery protects neonates from early onset group B streptococcal disease

Journal of Infectious Diseases

Volumn 209, Issue 5, 2014, Pages 781-788

  Baker, Carol J ^a,b   Carey, Vincent J ^a   Rench, Marcia A ^a   Edwards, Morven S ^a   Hillier, Sharon L ^c   Kasper, Dennis L ^a   Platt, Richard ^d  

^a Department of Pediatrics ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

glycoconjugate vaccine; Group B Streptococcus; immunization; meningitis; neonatal sepsis; neonate; protective immunity; serocorrelate

Indexed keywords

GLYCOCONJUGATE VACCINE; GROUP B STREPTOCOCCUS; IMMUNIZATION; MENINGITIS; NEONATAL SEPSIS; NEONATE; PROTECTIVE IMMUNITY; SEROCORRELATE;

ADULT; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; PROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS; VACCINATION; YOUNG ADULT;

EID: 84894270960     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit549     Document Type: Article

References (30)

1. Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: A study of 33 infants. J Pediatr 1973; 82:724-9.
2. Stoll BJ, Hansen NI, Sanchez PJ, et al. Early onset neonatal sepsis: The burden of group B streptococcal and E. coli disease continues. Pediatrics 2011; 127:817-26.
3. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753-6.
4. Baker CJ, Kasper DL, Tager IB, et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest 1977; 59:810-8.
5. Boyer KM, Papierniak CK, Gadzala CA, Parvin JD, Gotoff SP. Transplacental passage of IgG antibody to group B Streptococcus serotype Ia. J Pediatr 1984; 104:618-20.
6. Gotoff SP, Papierniak CK, Klegerman ME, Boyer KM. Quantitation of IgG antibody to the type-specific polysaccharide of group B Streptococcus type Ib in pregnant women and infected infants. J Pediatr 1984; 105:628-30.
7. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1-22.
8. Verani JR, McGee JL, Schrag SJ. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease-revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 5:1-36.
9. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179:142-50.
10. Baker CJ, Paoletti LC, Carey VJ, et al. Use of capsular polysaccharidetetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000; 182:1129-38.
11. Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188:66-73.
12. Baker CJ, Paoletti LC, Rench MA, Guttormsen H-K, Edwards MS, Kasper DL. Immune response of healthy women to two different type V group B streptococcal capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004; 189:1103-12.
13. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
14. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19:187-95.
15. Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis 2000; 30:276-81.
16. Campbell JR, Hillier SL, Krohn MA, et al. Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet Gynecol 2000; 96:498-503.
17. Lancefield R. Serologic differentiation of specific types of beta hemolytic streptococci. J Exp Med 1934; 59:441-58.
18. Guttormsen H-K, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis 1996; 173:142-50.
19. Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 1995; 96:600-3.
20. Lawless JF. Statistical models and methods for lifetime data. JohnWiley & Sons, New York, 1982:580.
21. Hirji KF, Mehta CR, Patel NR. Exact inference for matched casecontrol studies. Biometrics 1988; 44:803-14.
22. Carey VJ, Baker CJ, Platt R. Bayesian inference on protective antibody levels using case-control data. Biometrics 2001; 57:135-42.
23. Edwards MS, Nizet V, Baker CJ. Group B streptococcal infections. In: Remington JS, Klein JO, Wilson CB, Nizet V, Maldonado UA, eds. Infectious diseases of the fetus and newborn infant. 7th ed. Philadelphia, PA: Elsevier, 2011:419-69.
24. Gilks WR, Thomas A, Spiegelhalter DJ. A language and program for complex Bayesian modelling. Statistician 1994; 43:169-77.
25. Paoletti LC,Wessels MR, Rodewald A, Schroff AA, Jennings HJ, Kasper DL. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1994; 62:3236-43.
26. Lin F-YC, Clemens JD, Azimi PH, et al. Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J Infect Dis 1998; 177:790-2.
27. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056-65.
28. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-72.
29. Lin F-YC, Phillips JB III, Azimi PH, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: A multicenter, seroepidemiology study. J Infect Dis 2001; 184:1022-8.
30. Lin F-YC, Weisman LE, Azimi PH, et al. Level of maternal anti-IgG group B Streptococcus type III antibody correlated with protection of neonates against this pathogen. J Infect Dis 2004; 190: 928-34.